Medical
Biotechnology
Pharmaceutical

Progenics Pharmaceuticals

$4.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-2.37%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PGNX and other stocks, options, ETFs, and crypto commission-free!

About

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. Read More The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Employees
79
Headquarters
New York, New York
Founded
1986
Market Cap
382.98M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.36M
High Today
$4.73
Low Today
$4.48
Open Price
$4.64
Volume
837.49K
52 Week High
$9.42
52 Week Low
$3.62

Collections

Medical
Biotechnology
Pharmaceutical
Cancer Prevention
Therapy
Health
Technology

News

Seeking AlphaMar 14

Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker on Q4 2018 Results - Earnings Call Transcript

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Q4 2018 Earnings Conference Call March 14, 2019 8:30 AM ET Company Participants Melissa Downs - Associate Director, Investor Relations Mark Baker - Chief Executive Officer Bryce Tenbarge - Senior Vice President of Commercial Pat Fabbio - Executive Vice President & Chief Financial Officer Conference Call Participants Martin Auster - Credit Suisse Chad Messer - Needham & Company Tim Chiang - BTIG Biren Amin - Jefferies Operator Good day, ladies and gen...

313
Yahoo FinanceMar 14

Progenics (PGNX) Reports Q4 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of -10.53% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

114
Simply Wall StFeb 23

Is Progenics Pharmaceuticals, Inc.’s (NASDAQ:PGNX) CEO Pay Fair?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. The aim of all this is t...

528

Earnings

-$0.24
-$0.16
-$0.09
-$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.11 per share
Actual
-$0.17 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.